Citius Oncology, Inc. CTOR Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
- Citius Oncology, Inc. (CTOR) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $18.1M in Q3 2026.
- How has Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?
- Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number decreased by 0.0% year-over-year, from $18.1M to $18.1M.
- What is the long-term trend for Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?
- Over 3 years (2023 to 2026), Citius Oncology, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number has grown at a 12.8% compound annual growth rate (CAGR), from $12.6M to $18.1M.